A Vaccine Against Group B Streptococcus: Recent Advances

被引:91
作者
Carreras-Abad, Clara [1 ,2 ,3 ]
Ramkhelawon, Laxmee [1 ,2 ]
Heath, Paul T. [1 ,2 ]
Le Doare, Kirsty [1 ,2 ,4 ,5 ,6 ]
机构
[1] St Georges Univ London, Paediat Infect Dis Res Grp, Inst Infect & Immun, Jenner Wing,Level 2 Mailpoint J2C, London SW17 0RE, England
[2] St Georges Univ London, Vaccine Inst, Inst Infect & Immun, London, England
[3] Univ Autonoma Barcelona, Dept Paediat Obstet & Gynecol & Prevent Med & Pu, Barcelona, Spain
[4] Publ Hlth England, Pathogen Immun Grp, Porton Down, England
[5] MRC, Uganda Virus Res Inst, Entebbe, Uganda
[6] London Sch Hyg & Trop Med, Uganda Res Unit, Entebbe, Uganda
关键词
Group B streptococcus; Streptococcus agalactiae; maternal vaccines; maternal immunisation; neonatal sepsis; infant sepsis; PREGNANT-WOMEN; CAPSULAR POLYSACCHARIDE; INVASIVE DISEASE; COST-EFFECTIVENESS; MATERNAL ANTIBODY; SEROTYPE DISTRIBUTION; CONJUGATE VACCINE; VIRULENCE FACTORS; BIOFILM FORMATION; SURFACE-PROTEINS;
D O I
10.2147/IDR.S203454
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Group B streptococcus (GBS) causes a high burden of neonatal and infant disease globally. Implementing a vaccine for pregnant women is a promising strategy to prevent neonatal and infant GBS disease and has been identified as a priority by the World Health Organisation (WHO). GBS serotype-specific polysaccharide - protein conjugate vaccines are at advanced stages of development, but a large number of participants would be required to undertake Phase III clinical efficacy trials. Efforts are therefore currently focused on establishing serocorrelates of protection in natural immunity studies as an alternative pathway for licensure of a GBS vaccine, followed by Phase IV studies to evaluate safety and effectiveness. Protein vaccines are in earlier stages of development but are highly promising as they might confer protection irrespective of serotype. Further epidemiological, immunological and health economic studies are required to enable the vaccine to reach its target population as soon as possible.
引用
收藏
页码:1263 / 1272
页数:10
相关论文
共 107 条
[1]   Potential cost-effectiveness of a maternal Group B streptococcal vaccine in The Gambia [J].
Ahmed, N. ;
Giorgakoudi, K. ;
Usuf, E. ;
Okomo, U. ;
Clarke, E. ;
Kampmann, B. ;
Le Doare, K. ;
Trotter, C. .
VACCINE, 2020, 38 (15) :3096-3104
[2]   Effectiveness of maternal pertussis vaccination in England: an observational study [J].
Amirthalingam, Gayatri ;
Andrews, Nick ;
Campbell, Helen ;
Ribeiro, Sonia ;
Kara, Edna ;
Donegan, Katherine ;
Fry, Norman K. ;
Miller, Elizabeth ;
Ramsay, Mary .
LANCET, 2014, 384 (9953) :1521-1528
[3]   Neutrophil extracellular traps [J].
Amulic, Borko ;
Hayes, Garret .
CURRENT BIOLOGY, 2011, 21 (09) :R297-R298
[4]  
[Anonymous], WHO PREF PROD CHAR G
[5]  
[Anonymous], VACCINE
[6]  
[Anonymous], CLIN INFECT DIS
[7]  
Areschoug T, 1999, INFECT IMMUN, V67, P6350
[8]   Maternal Antibody at Delivery Protects Neonates From Early Onset Group B Streptococcal Disease [J].
Baker, Carol J. ;
Carey, Vincent J. ;
Rench, Marcia A. ;
Edwards, Morven S. ;
Hillier, Sharon L. ;
Kasper, Dennis L. ;
Platt, Richard .
JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (05) :781-788
[9]   Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib [J].
Baker, CJ ;
Paoletti, LC ;
Wessels, MR ;
Guttormsen, HK ;
Rench, MA ;
Hickman, ME ;
Kasper, DL .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) :142-150
[10]   Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines [J].
Baker, CJ ;
Paoletti, LC ;
Rench, MA ;
Guttormsen, HK ;
Edwards, MS ;
Kasper, DL .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (06) :1103-1112